Hyperpolarized 129Xe magnetic resonance imaging: tolerability in healthy volunteers and subjects with pulmonary disease.
Yajur Shukla, Andrew Wheatley, Miranda Kirby...
https://pubmed.ncbi.nlm.nih.gov/22591724Actively Recruiting
Age: 40Years - 85Years
All Genders
ID04761393
Characterizing Mmp12 In Sputum And Its Relationship To Emphysema And Inflammatory Endotypes
Led by McMaster University · Updated on 2024-11-20
45
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
M
McMaster University
Lead Sponsor
F
Foresee Pharmaceuticals Co., Ltd.
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying patients with emphysema to understand how high levels of an enzyme called matrix metalloproteinase-12 (MMP12) in sputum and blood relate to lung damage and immune system activity. The study focuses on the connection between MMP12 levels, airspace enlargement in the lungs, and specific immune biomarkers, using advanced imaging techniques to assess lung changes. Participants will undergo inhalation of a special gas mixture containing hyperpolarized xenon-129 for diffusion-weighted MRI scans, which helps measure alveolar airspace size. The study groups include patients with different inflammatory profiles based on blood and sputum cell counts. Researchers will use imaging and biomarker measurements at baseline to characterize lung destruction and immune activity. During the study, participants will have imaging with CT and MRI, as well as blood and sputum collections to measure MMP12 and type-2 immune markers. The research team will compare these measures with healthy individuals and assess their relationship to lung disease severity. The study enrolls adults aged 40 to 85 years and involves detailed lung function testing and biomarker analysis to better understand emphysema progression.
CONDITIONS
Brief Title
Characterizing Matrix Metalloproteinase-12 (MMP12) in Sputum
Who Can Participate
Age: 40Years - 85Years
All Genders
Eligibility Criteria
You may qualify if you...
- 40 years of age or older
- Current or former smokers with more than 10 pack years of smoking history
- Post-bronchodilator FEV1/FVC ratio less than 70% and FEV1 value 30% or higher predicted (GOLD 1, 2, or 3)
- Diagnosis of pulmonary emphysema confirmed by radiologist based on CT scan
- Normal controls have no significant medical conditions or history of respiratory diseases and no smoking history
- Normal controls have post-bronchodilator FEV1/FVC ratio greater than 70%
You will not qualify if you...
- Presence of non-COPD airway diseases
- Very severe COPD with FEV1 less than 30% predicted
- Current exacerbation of lung disease
- Life expectancy less than 3 months
- Pregnant or breastfeeding
- Undergoing immunomodulatory or biologic treatments
- Use of systemic steroids in the last month
- Hospitalization due to exacerbation in the last 12 months
- Known cardiovascular disease under treatment or recent hospitalization
- Inability to perform spirometry
- Active cancer
- Lung surgery during the study period
- History of alcohol or drug abuse preventing follow-up
- History of bronchial thermoplasty
- Participation in another clinical study
- Presence of metal implants or devices incompatible with MRI, such as pacemakers, artificial limbs, metallic fragments, surgical staples, or ear implants
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - 1 day
Participants undergo imaging and biomarker assessments to characterize lung condition and inflammation profiles.
1 visit (in-person)
Long-term Monitoring
Duration - Up to 1 year
Participants are observed over time to assess matrix metalloproteinase-12 (MMP12) levels and lung changes without receiving active treatment.
Follow-up visits may occur depending on cohort assignment
Trial Site Locations
Total: 1 location
1
Firestone Institute for Respiratory Health, St. Joseph's Healthcare
Hamilton, Ontario, Canada, L8N 4A6
Actively Recruiting
Loading map...
Research Team
S
Sarah Svenningsen, PhD
M
Melanie Kjarsgaard
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Relationship between pulmonary matrix metalloproteinases and quantitative CT markers of small airways disease and emphysema in COPD.
Kristoffer Ostridge, Nicholas Williams, Viktoriya Kim...
https://pubmed.ncbi.nlm.nih.gov/26645414Eosinophil peroxidase in sputum represents a unique biomarker of airway eosinophilia.
P Nair, S I Ochkur, C Protheroe...
https://pubmed.ncbi.nlm.nih.gov/23931643